BTIG analyst Marie Thibault raised the firm’s price target on DexCom to $150 from $125 and keeps a Buy rating on the shares as part of a broader research note on Medical Technology. The sector has seen a strong resurgence in recent weeks, and the recovery is warranted following months of panicked selling related to GLP-1 fears, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/2/2024
- DexCom participates in a conference call with William Blair
- William Blair says buy these stocks for 2024
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Tandem Diabetes launches updated t:slim X2 insulin pump software with DexCom CGM